Berhanu Alemayehu

Education

D.P.H., Health Policy/Health Economics, University of Michigan Ann Arbor United States

M.S., Statistics, University of Texas El Paso United States

Journal Articles

(2020). Budget impact analysis of introducing a non-reconstituted, hexavalent vaccine for pediatric immunization in the United Kingdom. EXPERT REVIEW OF VACCINES, 19(12). 1167-1175.

(2020). Budget impact analysis of introducing a non-reconstituted, hexavalent vaccine for pediatric immunization in the United Kingdom. EXPERT REVIEW OF VACCINES, 19(12). 1167-1175.

(2018). Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. 20(4). 821-830.

(2018). Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. 20(4). 821-830.

(2018). Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. 20(4). 821-830.

(2018). Costs associated with long-acting insulin analogues in patients with diabetes. The American journal of managed care, 24(8 Spec No.). SP265-SP272.

(2018). Costs associated with long-acting insulin analogues in patients with diabetes. The American journal of managed care, 24(8 Spec No.). SP265-SP272.

(2017). Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas. 31(11). 1620-1623.

(2017). Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas. 31(11). 1620-1623.

(2013). Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data. 35(12). 1923-32.

(2012). Esomeprazole formulary exclusion: impact on total health care services use and costs. 124(3). 149-63.

(2012). Proton pump inhibitor prescribing patterns in newborns and infants. 19(4). 283-7.

(2011). Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. 3. 233-45.

(2010). Proton Pump Inhibitor Use in Newborns and Infants. J Pediatric Gastroenterol Nutr 2010;51(Suppl 2). J Pediatric Gastroenterol Nutr 2010;51(Suppl 2).,

(2010). Cost sharing, adherence, and health outcomes in patients with diabetes. 16(8). 589-600.

(2009). A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clinical therapeutics, 31(3). 623-31.

(2009). Effect of drug therapy on HEDIS measurements of HbA1c control in diabetes patients. Managed care (Langhorne, Pa.), 18(2). 40-4.

(2009). Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005. 51(12). 1460-5.

(2007). Correlation of HEDIS diabetes health plan score with utilization of diabetes medications. 20(10). 14-7.

(2004). The lifetime distribution of health care costs. 39(3). 627-42.

(2002). Comparative analysis of two quality-of-life instruments for patients with chronic obstructive pulmonary disease. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 5(5). 437-42.

Conference Proceedings

Alemayehu, B. (2019). Timing of standalone vaccine administration in infants receiving DTaP based combination vaccines. ID Week, 2019.

Alemayehu, B. (2018). Preference differences between insulin glargine and MK-1293 pens among patients with diabetes and certified diabetes educators .

Alemayehu, B. (2018). Cost-effectiveness of Rotavirus vaccination in the Netherlands – a disease transmission dynamic modeling approach. Value in Health, Vol. 21, S3 (October 2018).

Alemayehu, B. (2018). Budget impact analysis of introducing a ready-to-use fully-liquid Pediatric Hexavalent vaccine for childhood immunization in the United Kingdom. Value in Health, Vol. 21, S3 (October 2018).

Alemayehu, B. (2018). Preference differences between insulin glargine and MK-1293 pens among patients with diabetes and certified diabetes educators. ADA.

Alemayehu, B. (2017). Methods for developing a preference and usability survey for devices: a case study in diabetes. ISPOR Value in Health.

Alemayehu, B. (2016). A UK Observational cohort study of insulin treatment patterns and characterization of insulin users in patients with T1DM and T2DM. Value in Health.

Alemayehu, B. (2016). Survival as a function of HbA1c in people with type 2 diabetes using differing glucose-lowering regimens. Poster presentation at the European Association for the Study of Diabetes (EASD), 52nd annual meeting.

Alemayehu, B. (2016). Healthcare Resource Use and Associated Costs for Type 2 Diabetes Patients Prescribed Sulfonylureas. Poster Presentation at the American Diabetes Association’s 76th Scientific Sessions.

Alemayehu, B. (2016). Survival in people with Type 2 diabetes with lower Glycosylated Haemoglobin. Oral presentation at the American Diabetes Association (ADA), 76th Scientific Sessions.

Alemayehu, B. (2015). A practical approach to understand the concepts and methods used to assess heterogeneity and inconsistency in Network Meta Analysis. Workshop presentation at the ISPOR 20th international annual meeting.

Alemayehu, B. (2014). Self reported health care resource use and indirect economic burden of opioid induced constipation (OIC). Poster presentation at the at the ISPOR 17th annual European Congress, Amsterdam, November 2014.

Alemayehu, B. (2012). Systematic literature review of economic costs in the US of Major Depressive Disorder in adults who are inadequate responders to initial treatment.

Alemayehu, B. (2012). Real-world US retrospective database analysis evaluating treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder newly treated with immediate release (IR) or extended release (XR) Quetiapine Fumarate.

Alemayehu, B. (2011). Impact on health care costs when formulary exclusion triggers switching of Proton Pump Inhibitor (PPI) therapy. Poster presented at the ACG 76th annual meeting.

Alemayehu, B. (2011). A US retrospective database analyses evaluating characteristics of patients with bipolar disorder prior to initiating treatment with immediate-release (IR) or extended-release (XR) quetiapine fumarate. Poster presented at the 11th annual IFMAD, Budapest.

Alemayehu, B. (2010). Cost analysis in managed care plans for patients with bipolar depression who initiated therapy with quetiapine XR and aripiprazole. Presented at the Annual Meeting of the College of Psychiatric and Neurologic Pharmacists.

Alemayehu, B. (2010). Treatment Patterns by Oncologists and Urologists for Castration-Resistant Prostate Cancer (CRPC). Poster presentation at ASCO, June 2010.

Alemayehu, B. (2010). Variations in Chemotherapy Treatment by Oncologists and Urologists for Patients with Castration-Resistant Prostate Cancer (CRPC). Poster presented at AMCP Educational Conference, October 2010.

Alemayehu, B. (2010). Differences in Healthcare Costs for Patients with Castration-resistant Prostate Cancer (CRPC) Treated by Oncologists or Urologists. Poster presented at ISPOR 13th Annual European Congress, Prague.

Alemayehu, B. (2010). Direct health care costs among patients with bipolar disorder who initiated therapy with aripiprazole or quetiapine XR.  Presented at the 15th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research .

Alemayehu, B. (2010). Impact on resource utilization and costs when formulary exclusion triggers switching of Proton Pump Inhibitor (PPI) therapy. Poster presented at Digestive Disease Week (DDW) annual meeting.

Alemayehu, B. (2010). Comparison of hospitalizations and costs among bipolar patients who switched to extended-release quetiapine from immediate-release quetiapine. Presented at the 163rd Annual Meeting of the American Psychiatric Association .

Alemayehu, B. (2009). Burden of Illness of Hormone-Resistant Prostate Cancer Patients in a Managed Care Population. Poster presentation at AMCP educational conference.

Alemayehu, B. (2009). Healthcare costs and utilization implications of exclusion of esomeprazole from a preferred formulary list of a national health plan. Poster presentation at American College of Gastroenterology (ACG) annual meeting.

Alemayehu, B. (2009). A prediction model to identify subjects with hormone refractory prostate cancer (HRPC) from a managed care administrative claims database. Poster presentation at ISPOR 14th Annual International Meeting.

Alemayehu, B. (2008). Utilization differences between Insulin Detemir (Levemir®) and Insulin Glargine (Lantus®) users. Poster presentation,  ADA 68th Annual Scientific Sessions.

Alemayehu, B. (2008). Determinants of insulin initiation for commercially insured adults with type 2 diabetes. Poster presentation,  ADA 68th Annual Scientific Sessions.

Alemayehu, B. (2008). Lost productivity associated with type 1 and type 2 diabetes in a commercially insured population. Presented at ISPOR 13th Annual International Meeting.

Alemayehu, B. (2008). Comparison of healthcare utilization and costs in type 2 diabetes patients initiating analog and human insulin. Poster presented at ISPOR 13th Annual International Meetings..

Alemayehu, B. (2008). Effect of patient cost-sharing and adherence to anti-diabetic medication on expenditure, utilization and complicatios. Podium presentation at the AcademyHealth annual research meeting.

Alemayehu, B. (2008). Differences in healthcare utilization and expenditures among type 2 diabetes Medicare patients initiating analog and human insulin. Podium presentation at the AcademyHealth annual research meeting.

Alemayehu, B. (2006). Impact of prescription drug benefit plan design on medication adherence. Poster presentation at the AcademyHealth annual research meetings.

Alemayehu, B. (2004). Impact of the Anthrax Bioterrorism Incidents of 2001 on Antibiotic Utilization. Presented as a poster at the annual research forum of the American College of Emergency Physicians.

Alemayehu, B. (2002). Improvements in guidelines-based asthma pharmacotherapy by a patient-focused disease management program. Podium presentation to the American College of Chest Physicians annual meeting .

Alemayehu, B. (2002). An epidemiological examination of medication resource use and costs among the insured elderly, presented at the  ISPOR 7th Annual International Meeting.

Alemayehu, B. (2001). Comparison of two quality of life instruments in patients with Chronic Obstructive Pulmonary Disease.  Presented at the ISPOR 6th Annual International Meeting.

Alemayehu, B. (2000). Lifetime distribution of Health Care Costs” – Presented at the faculty and staff of the School of Public Health at the University of Michigan.

Alemayehu, B. (1999). Antibiotic Usage for Viral Infections among the Insured Population in Michigan – Presented at the 1999 American Public Health Association Annual Meetin.

Alemayehu, B. (1999). Statistical Sampling for Medical Claims Audit” – Presented at the Blue Cross Blue Shield Association, National Internal Audit and Anti-Fraud Conference, Orlando Florida, May 1999..

Alemayehu, B. (1999). Statistical Comparison of Health Care Utilization Rates: A Multivariate Approach” – Presented at the Quality Assessment and Improvement Seminar, Blue Cross Blue Shield of Michigan, April 1999..

Alemayehu, B. Unnecessary Antibiotic Usage for Viral Infections” – Presented at the Michigan Antibiotic Resistance Reduction (MARR) task force, Detroit, Michigan, October 1998.

Professional